

Señora Directora

DIRECCION DE NUEVAS CREACIONES

Superintendencia de Industria y Comercio

E. S. D.

Referencia: Expediente No. NC2018/0008756

Solicitud de patente para: MOLÉCULAS QUE TIENEN UTILIDAD

Asunto: PLAGUICIDA, E INTERMEDIARIOS, COMPOSICIONES Y PROCESOS,
RELACIONADOS CON ELLAS

Solicitante: DOW AGROSCIENCES LLC

Fecha de solicitud: 22 de agosto de 2018

RECONOCIMIENTO DE EXAMEN DE PATENTABILIDAD DE LA USPTO

Yo, **ANDRÉS RINCÓN USCÁTEGUI**, obrando como apoderado del solicitante en el asunto antes identificado, respetuosamente manifiesto que de conformidad con lo dispuesto en la resolución No. 54093 de 2012, atentamente me permito solicitar el reconocimiento del resultado del Examen de Patentabilidad realizado por el Oficina Estadounidense de Marcas y Patentes, USPTO, a la solicitud 15/408,682, la cual es la prioridad invocada por la solicitud internacional US 201662286673P y US 201662286655P, correspondiente a la solicitud en fase nacional en Colombia anteriormente referenciada. Lo anterior, teniendo en cuenta los siguientes documentos:

1. Formulario de procedimiento acelerado de exámenes de patente (PPH).
2. Notificación de aceptación de la solicitud (Notice of Allowance) de fecha 03 de agosto de 2018 emitido por la USPTO como Oficina de Examen Anterior (OEA), con su respectiva traducción al Español.
3. Traducción de las reivindicaciones concedidas por la USPTO;
4. Memorial de modificaciones voluntarias;

INNOVACIÓN PARA LOS NEGOCIOS

BOGOTÁ DC, 110221 - COLOMBIA - Edificio Siski - Carrera 4 No. 72A - 35 - Tel. (57-1) 347 3611 - Fax (57-1) 211 8650
MEDELLÍN, 050021 - COLOMBIA - San Fernando Plaza - Carrera 42A No. 1 - 25 Torre 4 Oficina 303 - Teléfono: (57-4) 520 4760
BARRANQUILLA, 080002 - COLOMBIA - Calle 64 No. 50 - 22, Oficina 201 - Teléfono: (57-5) 351 6440
www.cavelier.com
cavelier@cavelier.com

- 5. Pliego reivindicatorio modificado conformado por **17** reivindicaciones, que se basa en el capítulo concedido por la USPTO;
- 6. Comprobante de pago por concepto de modificación del pliego reivindicatorio;
- 7. Pago en línea por concepto de tasa por 7 reivindicaciones adicionales.
- 8. Finalmente, aporto a continuación una tabla donde se consignan la correspondencia de las reivindicaciones que han sido determinadas como patentables u otorgables en la USPTO y aquellas presentadas junto con el presente memorial como modificación voluntaria:

TABLA DE CORRESPONDENCIA	
Nuevo pliego de reivindicaciones presentadas ante SIC como OSP junto con el presente memorial	Reivindicaciones concedidas por la USPTO, 15/408,682
Reivindicación 1	Reivindicación 1
Reivindicación 2	Reivindicación 2
Reivindicación 3	Reivindicación 3
Reivindicación 4	Reivindicación 4
Reivindicación 5	Reivindicación 5
Reivindicación 6	Reivindicación 6
Reivindicación 7	Reivindicación 7
Reivindicación 8	Reivindicación 8
Reivindicación 9	Reivindicación 9
Reivindicación 10	Reivindicación 10
Reivindicación 11	Reivindicación 11
Reivindicación 12	Reivindicación 12
Reivindicación 13	Reivindicación 13
Reivindicación 14	Reivindicación 14
Reivindicación 15	Reivindicación 15
Reivindicación 16	Reivindicación 16
Reivindicación 17	Reivindicación 17

Cumplido así con lo dispuesto para que una solicitud sea aceptada en el Procedimiento Acelerado de Estudio de Solicitudes de Patentes entre la USPTO actuando como Oficina de Examen Anterior (OEA) y la SIC, atentamente solicito que se continúe con el trámite correspondiente a esta solicitud de Patente de Invención.

Señora Directora,

ANDRÉS RINCÓN USCÁTEGUI

C.C. 79.780.910 de Bogotá

T.P. 114.908

COLO-10975-0841-0431-1
NBV\CVN\ID-304411\WPC10975
No. M-2019-304411\NBV

	Espacio reservado para el adhesivo de radicación
---	--

DIRECCIÓN DE NUEVAS CREACIONES
Procedimiento acelerado de exámenes de patente (PPH)

1	NÚMERO DE SOLICITUD ANTE LA SIC	NC2018/0008756	
2	OFICINA DE PRIMERA PRESENTACIÓN (OPP)	Estados Unidos de América	
3	NÚMERO(S) DE SOLICITUD O PUBLICACIÓN DE LA(S) SOLICITUD(ES) (OPP):	15/408,682	
4	☐ REPRESENTANTE LEGAL ☒ APODERADO		
APELLIDOS RINCÓN USCÁTEGUI		NOMBRES ANDRÉS	IDENTIFICACIÓN C.C.79.780.910 T.P. 114.908
DIRECCIÓN	Cra 4a No. 72-35	No. TELÉFONO	3473611
CIUDAD	Bogotá	CORREO ELECTRÓNICO	cavelier@cavelier.com
PAÍS	Colombia	No. RADICACIÓN O PROTOCOLO DE PODER GENERAL	
5	CONDICIONES PARA ACCEDER A ESTE PROCESO:		
5.1.	DATOS DE PRIORIDAD ☒ SI ☐ NO		
(33) PAÍS DE ORIGEN		CÓDIGO PAÍS	(31) NÚMERO
ESTADOS UNIDOS DE AMERICA		US	62/286,655
ESTADOS UNIDOS DE AMERICA		US	62/286,673
(32) FECHA(AAAA/MM/DD)			
2016/01/25			
2016/01/25			
5.2.	DATOS SOLICITUD INTERNACIONAL PCT ☒ SI ☐ NO		
Solicitud Internacional No.	PCT/US2017/013910	Fecha	2017/01/18
Publicación Internacional No.	WO 2017/132022	Fecha	2017/08/03
El solicitante presenta una copia de la(s) reivindicación(es) patentable(s) u otorgable(s) de la solicitud de la Oficina de Primera Presentación que profirió el examen de patentabilidad, junto con una traducción al castellano. ☒ SI ☐ NO			
6	TABLA DE CORRESPONDENCIA DE REIVINDICACIONES		
Reivindicaciones de la solicitud en Colombia	Reivindicaciones otorgables en la solicitud internacional USPTO	Explicación sobre la suficiente correspondencia o Comentarios que explican la correspondencia	
1-17	1-17	Las reivindicaciones 1 a 17 del pliego reivindicatorio de la solicitud de patente NC2018/0008756 que se presentan por medio de las modificaciones voluntarias solicitadas, corresponden a las reivindicaciones 1 a 17 otorgadas por la Oficina de Marcas y Patentes de Estados Unidos de América.	

REQUISITOS PARA EL RECONOCIMIENTO DE LOS RESULTADOS DE EXÁMENES DE PATENTABILIDAD EFECTUADOS A SOLICITUDES EXTRANJERAS	
Para que la Superintendencia de Industria y Comercio pueda reconocer los resultados de exámenes de patentabilidad producidos por otras Oficinas de Propiedad Industrial se debe cumplir con las siguientes condiciones: (a) Al momento de solicitar el examen de patentabilidad, si el solicitante pide que se reconozcan exámenes de patentabilidad de otras oficinas extranjeras, deberá aportar junto con el pago de la tasa correspondiente, los siguientes anexos: (i) Copia de las resoluciones, fallos o decisiones que han sido relevantes para la determinación de la patentabilidad de la(s) solicitud(es) en la Oficina que haya proferido el examen de patentabilidad que contienen reivindicaciones patentables u otorgables que son la base de la petición, y si es del caso, su traducción al castellano. ☒ SI ☐ NO (ii) Copia de todas las reivindicaciones determinadas como patentables u otorgables en la Oficina que profirió el examen de patentabilidad y, si es del caso, su traducción al castellano. ☒ SI ☐ NO (iii) Copia de los antecedentes, información o documentos citados por el examinador de la Oficina de Primera Presentación del examen de patentabilidad, en las resoluciones, fallos o decisiones correspondientes, incluyendo la literatura no patente. Los documentos de patente deberán presentarse siempre y cuando no estén disponibles para la Superintendencia de Industria y Comercio mediante el simple acceso a bases de datos gratuitas. ☐ SI ☒ NO (iv) Una tabla de correspondencias de las reivindicaciones que han sido determinadas como patentables u otorgables en la solicitud de la Oficina que haya proferido el examen de patentabilidad. ☒ SI ☐ NO	
7	FIRMA DEL SOLICITANTE, DEL APODERADO O DEL REPRESENTANTE LEGAL
ANDRÉS RINCÓN USCÁTEGUI C.C. No. 79.780.910 de Bogotá T.P.A. No. 114.908 del C.S.J.	



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

25212 7590 11/14/2017
DOW AGROSCIENCES LLC
9330 ZIONSVILLE RD
INDIANAPOLIS, IN 46268

EXAMINER

CHEN, PO-CHIH

ART UNIT

PAPER NUMBER

1626

DATE MAILED: 11/14/2017

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

15/408,682

01/18/2017

Thomas Barton

77284-US-NP

7972

TITLE OF INVENTION: MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	02/14/2018

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Maintenance fees are due in utility patents issuing on applications filed on or after Dec. 12, 1980. It is patentee's responsibility to ensure timely payment of maintenance fees when due. More information is available at www.uspto.gov/PatentMaintenanceFees.

PART B - FEE(S) TRANSMITTAL

**Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885**

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

25212 7590 11/14/2017
DOW AGROSCIENCES LLC
9330 ZIONSVILLE RD
INDIANAPOLIS, IN 46268

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/408,682	01/18/2017	Thomas Barton	77284-US-NP	7972

TITLE OF INVENTION: MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	02/14/2018

EXAMINER	ART UNIT	CLASS-SUBCLASS
CHEN, PO-CHIH	1626	514-521000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.	2. For printing on the patent front page, list (1) The names of up to 3 registered patent attorneys or agents OR, alternatively, 1 _____ (2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 2 _____ 3 _____
---	---

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:

- ☐ Issue Fee
☐ Publication Fee (No small entity discount permitted)
☐ Advance Order - # of Copies _____

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

- ☐ A check is enclosed.
☐ Payment by credit card. Form PTO-2038 is attached.
☐ The director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- ☐ Applicant certifying micro entity status. See 37 CFR 1.29
☐ Applicant asserting small entity status. See 37 CFR 1.27
☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____
 Typed or printed name _____ Registration No. _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/408,682	01/18/2017	Thomas Barton	77284-US-NP	7972
25212 7590 11/14/2017 DOW AGROSCIENCES LLC 9330 ZIONSVILLE RD INDIANAPOLIS, IN 46268			EXAMINER CHEN, PO-CHIH	
			ART UNIT 1626	PAPER NUMBER
DATE MAILED: 11/14/2017				

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 15/408,682	Applicant(s) BARTON ET AL.	
	Examiner PO-CHIH CHEN	Art Unit 1626	AIA (First Inventor to File) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the amendment file 8/11/2017.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are 1-6, 8-14, and 17-22. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

- a) ☐ All b) ☐ Some *c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|---|--|
| 1. ☐ Notice of References Cited (PTO-892) | 5. ☒ Examiner's Amendment/Comment |
| 2. ☒ Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date <u>8/11/2017</u> | 6. ☒ Examiner's Statement of Reasons for Allowance |
| 3. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material | 7. ☐ Other _____. |
| 4. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____. | |

DETAILED ACTION

- 1.** This office action is a response to Applicant's amendments/remarks after non-final rejection filed 8/11/2017.
- 2.** As filed, claims 1-6, 8-14, 17, 18, 21, and 22 are pending, wherein claims 21 and 22 are new; claims 19 and 20 are withdrawn; and claims 7, 15, and 16 are cancelled.
- 3.** The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA.

Response to Amendments/Remarks

Applicant's amendments/remarks, filed 8/11/2017, with respect to claims 1-18, have been fully considered and are entered. The status for each rejection in the previous Office Action is set out below.

- 4.** The § 112(b) indefinite rejection of claims 15, 16, and 18 is withdrawn per remarks and cancellation of claims 15 and 16.
- 5.** The § 112 fourth paragraph rejection of claims 7 and 12 is withdrawn per amendment and cancellation of claim 7.

Election/Restrictions

6. Claims 1-6, 8-14, 17, 18, 21, and 22 are directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claims 19 and 20, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104.

Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, **the restriction requirement as set forth in the Office action mailed on 4/7/2017 is hereby withdrawn.** In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Information Disclosure Statement

7. The information disclosure statement (IDS) submitted on 8/11/2017 has been considered by the Examiner.

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Carl Corvin on 11/3/2017.

The application has been amended as follows:

- 8.** In claim 1 (pg. 2, line 12 of the claim), amend the following:

Before "F, Cl, Br, I, CN";

After "R¹⁰ is selected from the group consisting of"; and

Delete "(F),".

- 9.** In claim 19 (pg. 4, line 1 of the claim), amend the following:

Before "said process comprising";

After "A process to control a pest"; and

Insert -- , wherein --.

- 10.** In claim 20 (pg. 4, lines 1-2 of the claim), amend the following:

Before "comprising applying a molecule";

After "A process"; and

Insert -- to control endoparasites and/or ectoparasites, wherein said process --.

Before “1 to a locus that includes”;

After “a molecule according to”; and

Insert -- claim --.

Before “.” (which is a period);

After “that includes a non-human animal”; and

Delete “to control endoparasites and/or ectoparasites”.

(All the abovementioned amendments are only for clarity and do not change the scope of the abovementioned claims).

Statement of Reasons for Allowance

11. The following is an examiner’s statement of reasons for allowance:

The instant invention pertains to a compound of instant Formula one or a method of controlling pest via the compound thereof. The instant compounds are free of the prior art; i.e., the genus of the compounds is novel and non-obvious. Accordingly, the method of treatment via the compound thereof is also free of the prior art; i.e. novel and non-obvious.

Relevant prior art, which discloses compounds that are closely related to the instant compounds is U.S. Patent Application Publication No. 2012/0329649, hereinafter

Art Unit: 1626

Hunter (See PTO-892 form mailed on 4/7/2017). The instant compounds are patentably distinct from the compounds disclosed in Hunter because the presence of the fluorine atom and its location. One of skill in the art would not be motivated to modify the prior art compounds and arrive at the presently claimed invention with a reasonable expectation of success and identical activity.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

12. Claims 1-6, 8-14 and 17-22 are allowed.

13. Claims 7, 15, and 16 are cancelled.

Telephone Inquiry

14. Any inquiry concerning this communication or earlier communications from the examiner should be directed to:

**PO-CHIH CHEN
(571) 270-7243**

The Examiner can normally be reached on Monday-Friday: 9:00am - 5:00pm EST. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Joseph McKane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 15/408,682
Art Unit: 1626

Page 7

/Po-Chih Chen/
Patent Examiner, Art Unit 1626
11/3/2017

/Alicia L Otton/
Primary Examiner, Art Unit 1626

Search Notes 	Application/Control No. 15408682	Applicant(s)/Patent Under Reexamination BARTON ET AL.
	Examiner PO-CHIH CHEN	Art Unit 1626

CPC- SEARCHED		
Symbol	Date	Examiner
c07d - limited by text	3/30/2017	pcc
c07c - limited by text	3/30/2017	pcc
a01n - limited by text	3/30/2017	pcc

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

SEARCH NOTES		
Search Notes	Date	Examiner
ads; abstract; bib datasheet reviewed	3/30/2017	pcc
STN search, history included	3/30/2017	pcc
EAST search, history included	3/30/2107	pcc
inventor search, using EAST	3/30/2017	pcc
patentability conference with alicia otton (primary)	11/3/2017	pcc
IDS considered	11/3/2017	pcc

INTERFERENCE SEARCH			
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner
c07d - limited by text		11/3/2017	pcc

--	--

INTERFERENCE SEARCH

US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner
c07c - limited by text		11/3/2017	pcc
a01n - limited by text		11/3/2017	pcc
INTEREFEREN CE	STN search, history included	11/3/2017	pcc

--	--

Doc code: IDS

PTO/SB/08a (01-10)

Doc description: Information Disclosure Statement (IDS) Filed

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		15408682
	Filing Date		2017-01-18
	First Named Inventor	Thomas Barton	
	Art Unit	1626	
	Examiner Name	CHEN, PO-CHIH	
	Attorney Docket Number	77284-US-NP	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	7375232	B2	2008-05-20	Clark et al.	
	2	7951828	B1	2011-05-31	Mita et al.	
	3					
	4					
	5					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20020068838	A1	2002-06-06	Demasse et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number 15408682

Filing Date 2017-01-18

First Named Inventor Thomas Barton

Art Unit 1626

Examiner Name CHEN, PO-CHIH

Attorney Docket Number 77284-US-NP

2	20120329649	A1	2012-12-27	Hunter et al.	
3	20140171308	A1	2014-06-19	Lo et al.	
4	20140171309	A1	2014-06-19	Lo et al.	
5	20140171310	A1	2014-06-19	Lo et al.	
6	20140171311	A1	2014-06-19	Lo et al.	
7	20140171312	A1	2014-06-19	Lo et al.	
8	20140171313	A1	2014-06-19	Lo et al.	
9	20140171314	A1	2014-06-19	Lo et al.	
10	20140171315	A1	2014-06-19	Lo et al.	
11	20150353477	A1	2015-12-10	LePlae et al.	
12	20170210723	A1	2017-07-25	LePlae et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	15408682
Filing Date	2017-01-18
First Named Inventor	Thomas Barton
Art Unit	1626
Examiner Name	CHEN, PO-CHIH
Attorney Docket Number	77284-US-NP

13	20170208803	A1	2017-07-25	Thomas et al.	
14	20170208810	A1	2017-07-25	Thomas et al.	
15	20170208804	A1	2017-07-25	Thomas et al.	
16	20170208806	A1	2017-07-25	Thomas et al.	
17	20080063678	A1	2008-03-13	von Deyn et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2017132022	WO	A1	2017-08-03	Dow AgroSciences LLC	International Search Report and the Written Opinion of the International Searching Authority of PCT for WO	☐
	2	2014100163	WO	A1	2014-06-26	Dow AgroSciences LLC		☐
	3	2014100206	WO	A1	2014-06-26	Dow AgroSciences LLC		☐
	4	2010078300	WO	A1	2010-07-08	University of Alabama, Monash University, and Quee		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15408682
Filing Date	2017-01-18
First Named Inventor	Thomas Barton
Art Unit	1626
Examiner Name	CHEN, PO-CHIH
Attorney Docket Number	77284-US-NP

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	CORNELL Environmental Backgrounder: Pesticides and Food Safety (http://psep.cce.cornell.edu/issues/foodsafety-issues.aspx , cached June 29, 2010)	☐
	2	Taylor et al. (editor, "Pesticide Residues in Coastal Tropical Ecosystems: Distribution, Fate, and Effects" pg. 204, 2003).	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/PO-CHIH CHEN/	Date Considered	11/04/2017
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

EAST Search History

EAST Search History (Interference)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	0	"c07d.cpcl"	US-PGPUB; USPAT	OR	ON	2017/11/04 09:29
L2	219128	c07c.cpcl.	US-PGPUB; USPAT	OR	ON	2017/11/04 09:29
L3	64367	a01n.cpcl.	US-PGPUB; USPAT	OR	ON	2017/11/04 09:29
L4	277002	1 2 3	US-PGPUB; USPAT	OR	ON	2017/11/04 09:31
L5	53	4 and ((but-1-en-1-yl) same (benzamide or benzothioamide))	US-PGPUB; USPAT	OR	ON	2017/11/04 09:32
S16	69	((("GAO") near3 ("Xin")).INV.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:08
S17	38	((("HUNTER") near3 ("Jim")).INV.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:08
S18	29	((("LEPLAE") near3 ("Paul")).INV.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:08
S19	0	((("LAWLER") near3 ("Lori")).INV.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:08
S20	291	((("LO") near3 ("William")).INV.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:09
S21	18	((("PETKUS") near3 ("Jeff")).INV.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:09
S22	30	((("BORUWA") near3 ("Joshodeep")).INV.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:09
S23	16	((("TANGI RALA") near3 ("Raghuram")).INV.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:09
S24	55	((("WATSON") near3 ("Gerald")).INV.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:09
S25	636	((("HERBERT") near3 ("John")).INV.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:09
S26	103	((("BARTON") near3 ("Thomas")).INV.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:09
S27	1689	(dow adj agrosiences).as.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:09
S28	2798	S16 S17 S18 S19 S20 S21 S22 S23 S24 S25 S26 S27	US-PGPUB; USPAT	OR	ON	2017/03/28 23:09
S29	31	S28 and ((but-1-en-1-yl) same (benzamide or benzothioamide))	US-PGPUB; USPAT	OR	ON	2017/03/28 23:11
S30	1	"9211281".pn.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:15
S31	1	"9211280".pn.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:20
S32	1	"20020068838".pn.	US-PGPUB; USPAT	OR	ON	2017/03/28 23:24

11/ 4/ 2017 9:32:29 AM

**C:\Users\pchen1\Documents\EAST\Workspaces\331 - 15408634 - molecuels having
pesticidal utility, and intermediates, compositions, and processes, related thereto.wsp**

Número de solicitud/control: 15/408.682

Unidad Revisora: 1626

ACCIÓN DETALLADA

1. Este oficio es una respuesta a las modificaciones / comentarios del Solicitante posterior al rechazo no final presentado el 11/08/2017.
2. Tal como se presentaron, las reivindicaciones 1 a 6, 8 a 14, 17, 18, 21 y 22 están pendientes, en donde las reivindicaciones 21 y 22 son nuevas; las reivindicaciones 19 y 22 se eliminaron; y las reivindicaciones 7, 15 y 16 se cancelaron.
3. La presente solicitud, presentada el 16 de marzo de 2013 o posterior a esta fecha, se encuentra siendo examinada bajo el primer inventor que presenta las disposiciones de la AIA.

Respuesta a los modificaciones / comentarios

Se han ingresado y considerado en su totalidad las modificaciones / comentarios presentados el 11/08/2017 en relación con las reivindicaciones 1 a 18. El estado de cada rechazo en el oficio anterior se expone a continuación.

4. El rechazo indefinido conforme a la § 112 (b) de las reivindicaciones 15, 16 y 18 se elimina por los comentarios y cancelación de las reivindicaciones 16 y 16.
5. El rechazo en el párrafo cuarto conforme a la § 112 (b) de las reivindicaciones 7 y 12 se elimina por la modificación y cancelación de la reivindicación 7.

Elección/Restricciones

6. Las reivindicaciones 1 a 6, 8 a 14, 17, 18, 21 y 22 se refieren a un producto admisible. De conformidad con los procedimientos establecidos en la norma MPEP § 821.04 (B), las reivindicaciones 19 y 20, dirigidas al proceso de hacer o utilizar un producto permitido, previamente no tomadas en consideración debido resultado de un requerimiento de restricción, por medio de la presente se vuelven a incorporar y a examinar en su totalidad en virtud de la norma 37 CFR 1.104.

Ya que se han reincorporando todas las reivindicaciones que no se tomaron en consideración en virtud de la normas 37 CFR 1.104, **el requerimiento de restricción tal como se estableció en el oficio enviado por correo el día 07/04/2017 se elimina por medio del presente documento.** En vista de la eliminación del requerimiento de restricción en cuanto a las invenciones reincorporadas, se le informa al solicitante(s) que si cualquier reivindicación presentada en una solicitud de continuación o divisional es anticipada por, o incluye todas las limitaciones de una reivindicación que es admisible en la presente solicitud, dicha reivindicación puede estar sujeta a rechazos por doble

patentamiento provisional estatutario y/o no estatutario sobre las reivindicaciones de la presente solicitud. Una vez se elimine el requerimiento de restricción, las disposiciones de la norma 35 U.S.C. 121 ya no son aplicables. Ver *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). Ver también la norma MPEP § 804.01.

Declaración de divulgación de información

- 7.** El Examinador ha considerado la declaración de divulgación de información (IDS) enviada el 11/08/2017.

Modificaciones del Examinador

A continuación se encuentra una modificación por parte del examinador. Si el solicitante considera que los cambios y/o adiciones no son aceptables, se puede presentar una modificación de conformidad con la norma 37 CFR 1.312. Con el fin de asegurar que se tenga en cuenta dicha modificación, DEBE enviarse antes del pago de la tasa de emisión.

La modificación del examinador se autorizó mediante una entrevista telefónica con Carl Corvin el día 03/11/2017.

La solicitud se ha modificado de la siguiente manera:

- 8.** En la reivindicación 1 (pg. 2, línea 12 de la reivindicación) corregir lo siguiente:

Antes "F, Cl, Br, I, CN";

Después "R¹⁰ se selecciona del grupo que consiste en"; y

Eliminar "(F),".

- 9.** En la reivindicación 19 (pg. 4, línea 1 de la reivindicación), corregir lo siguiente:

Antes "dicho proceso que comprende";

Después "Un proceso para controlar una plaga"; e

Insertar --, en el que --.

- 10.** En la reivindicación 20 (pg. 4, líneas 1-2 de la reivindicación), corregir lo siguiente:

Antes "que comprende aplicar una molécula";

Después “Un proceso”; e

Insertar --, para controlar endoparásitos y/o ectoparásitos, en el que dicho proceso--.

Antes “1 a un locus que incluye”;

Después “una molécula de acuerdo con”; e

Insertar –la reivindicación--.

Antes “.” (el cual es un punto);

Después “que incluye un animal no humano”; y

Eliminar “para controlar endoparásitos y/o ectoparásitos”.

(Todas las modificaciones mencionadas con anterioridad son únicamente por claridad y no cambian el alcance de las reivindicaciones mencionadas anteriormente).

Declaración de razones para la aprobación

11. A continuación se encuentra la declaración del examinador en cuanto a las razones para la aprobación:

La presente invención pertenece a un compuesto de Fórmula (I) o un método para controlar plagas a través de su compuesto. Los compuestos no están comprendidos en el arte previo; es decir, el gen de los compuestos es novedoso y no es obvio, por lo que el método de tratamiento a través de su compuesto tampoco está comprendido en el arte previo; es decir, novedoso y no obvio.

El arte previo que divulga compuestos que más están relacionados con los compuestos de la presente solicitud es la Publicación de Solicitud de Patente de Estados Unidos No. 2012/0329649, de aquí en adelante denominada **Hunter** (Ver el formato PTO-892 enviado por correo el 07/04/2017). Los compuestos de la presente solicitud son patentablemente distintos de los compuestos divulgados en Hunter debido a la presencia del átomo de flúor y su posición. Una persona versada en la materia no sería motivada a modificar los compuestos del arte previo y llegar a la invención actualmente reivindicada con una expectativa razonable de tener éxito y una actividad idéntica.

Cualquier comentario que el solicitante considere necesario puede remitirse antes del pago de la tarifa de emisión y, a fin de evitar demoras en el trámite, debería venir junto con la tarifa de emisión. Dichos envíos deben marcarse de manera clara de la siguiente manera: "Comentarios sobre la Declaración de las Razones para la Aprobación".

Conclusiones

12. Se aprueban las reivindicaciones 1 a 6, 8 a 14, y 17 a 22

13. Se cancelan las reivindicaciones 7, 15 y 16.

Consulta telefónica

14. Cualquier pregunta relacionada con esta comunicación o cualquier comunicación previa por parte del examinador debe ser consultada con:

PO-CHIH CHEN

(571)270-7243

El examinador normalmente puede ser contactado de lunes a viernes de 9:00am a 5:00pm (Horario del este). En caso de no poder contactar al examinador vía telefónica, su supervisor, Joseph McKane puede ser contactado al (571)272-0699. El número de fax para la organización donde esta solicitud o trámite se encuentra asignado es 571-273-8300.

/PO-CHI CHEN/


Examinador de patentes, Unidad Revisora 1626

03/11/2017

/Alicia L Otton/

Examinador Principal, Unidad Revisora 1626


TABLE CD1



No.	R ¹⁰	5 $\mu\text{g}/\text{cm}^2$		0.5 $\mu\text{g}/\text{cm}^2$		0.05 $\mu\text{g}/\text{cm}^2$	
		BAW	CL	BAW	CL	BAW	CL
FC1	H	7*	100	0	0	0	0
F7	Cl	100	100	100	100	79	100
F4	Br	100	100	100	100	100	100
F33	CH ₃	100	100	100	100	88	100
F5	CF ₃	100	100	100	100	100	100

*Percent control (or mortality)

TABLE CD2




No.	R ¹⁰	5 $\mu\text{g}/\text{cm}^2$		0.5 $\mu\text{g}/\text{cm}^2$		0.05 $\mu\text{g}/\text{cm}^2$	
		BAW	CL	BAW	CL	BAW	CL
FC2	H	100*	100	0	6	0	0
F9	Cl	100	100	100	100	100	100
F3	Br	100	100	100	100	100	100
F2	CH ₃	100	100	100	100	100	100
F1	CF ₃	100	100	100	100	100	100

*Percent control (or mortality)

The invention claimed is:

1. A molecule having the following formula



wherein:

- (A) R¹, R⁵, R⁶, R¹¹, R¹², R¹³, and R¹⁴ are each independently selected from the group consisting of H, F, Cl, Br, I, CN, (C₁-C₄)alkyl, (C₁-C₄)haloalkyl, (C₁-C₄)alkoxy, and (C₁-C₄)haloalkoxy;
- (B) R², R³, and R⁴ are each independently selected from the group consisting of H, F, Cl, Br, I, CN, (C₁-C₄)

alkyl, (C₂-C₄)alkenyl, (C₂-C₄)alkynyl, (C₁-C₄)haloalkyl, (C₁-C₄)alkoxy, and (C₁-C₄)haloalkoxy;(C) R⁷ is (C₁-C₆)haloalkyl;(D) R⁹ is selected from the group consisting of H, F, Cl, Br, I, CN, (C₁-C₄)alkyl, (C₁-C₄)haloalkyl, (C₁-C₄)alkoxy, and (C₁-C₄)haloalkoxy;(E) R¹⁰ is selected from the group consisting of F, Cl, Br, I, CN, (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₂-C₄)alkynyl, (C₁-C₄)haloalkyl, (C₁-C₄)alkoxy, and (C₁-C₄)haloalkoxy;(F) R⁹ and R¹⁰ together can optionally form a 3- to 5-membered saturated or unsaturated, hydrocarbyl link, wherein said hydrocarbyl link may optionally be substituted with one or more substituents independently selected from the group consisting of F, Cl, Br, I, and CN;(G) L is (C₁-C₆)alkyl;(H) X is selected from the group consisting of C, S, and P(C₁-C₆)alkyl;




(I) n is 1 or 2;

165

- (J) R¹⁵ is selected from the group consisting of (C₁-C₄) alkyl, (C₂-C₄)alkenyl, (C₃-C₄)cycloalkyl, (C₁-C₄)haloalkyl, (C₁-C₄)alkoxy, (C₁-C₄)haloalkoxy, phenyl, and NH(C₃-C₄)cycloalkyl, wherein each alkyl, alkenyl, cycloalkyl, haloalkyl, alkoxy, haloalkoxy, and phenyl may optionally be substituted with one or more substituents independently selected from the group consisting of F, Cl, Br, I, CN, and OH; and agriculturally acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, resolved stereoisomers, and tautomers, of the molecules of Formula One.
2. A molecule according to claim 1 wherein R¹, R³, R⁴, R⁵, R⁶, R⁹, R¹¹, R¹², R¹³, and R¹⁴ are H.
3. A molecule according to claim 1 wherein R² is Cl, Br, or CH₃.
4. A molecule according to claim 1 wherein R³ is F, Cl, Br, or CH=CH₂.
5. A molecule according to claim 1 wherein R⁴ is Cl, Br, or CH₃.
6. A molecule according to claim 1 wherein R², R³, and R⁴ are Cl.
7. A molecule according to claim 1 wherein R⁷ is CF₃, CF₂CH₃, or CF₂CH₂CH₃.
8. A molecule according to claim 1 wherein R¹⁰ is Cl, Br, I, CH₃, or CF₃.
9. A molecule according to claim 1 wherein L is CH(CH₃) or CH(CH₂CH₃).

166

10. A molecule according to claim 1 wherein X is C or S.
11. A molecule according to claim 1 wherein n is 1.
12. A molecule according to claim 1 wherein R¹⁵ is CH₂CH₃, cyclopropyl, CH₂CF₃, CH₂CH₂CF₃, or NHcyclopropyl.
13. A molecule according to claim 1 wherein
- (A) R¹, R⁵, R⁶, R¹¹, R¹², R¹³, and R¹⁴ are H;
- (B) R², R³, and R⁴ are each independently selected from the group consisting of H, F, Cl, Br, (C₁-C₄)alkyl, (C₂-C₄)alkenyl;
- (C) R⁷ is (C₁-C₆)haloalkyl;
- (D) R⁹ is H;
- (E) R¹⁰ is selected from the group consisting of Cl, Br, (C₁-C₄)alkyl, and (C₁-C₄)haloalkyl;
- (G) L is (C₁-C₆)alkyl;
- (H) X is C or S;
- (I) n is 1 or 2;
- (J) R¹⁵ is selected from the group consisting of (C₁-C₄) alkyl, (C₃-C₄)cycloalkyl, (C₁-C₄)haloalkyl, and NH(C₃-C₄)cycloalkyl, wherein each alkyl, alkenyl, cycloalkyl, haloalkyl, alkoxy, haloalkoxy, and phenyl may optionally be substituted with one or more substituents independently selected from the group consisting of F, Cl, Br, I, CN, and OH.
14. A molecule according to claim 1 wherein said molecule is selected from one of the molecules in the following Table


No.	Structure
F1	
F2	
F3	

-continued


No.

Structure


F4




F5




F6




F7









F8



F9



-continued

No.	Structure
F10	
F11	
F12	
F13	
F14	
F15	

-continued

No.	Structure
F16	
F17	
F18	
F19	
F20	
F21	

-continued


No.	Structure
F22	
F23	
F24	
F25	
F26	
F27	

-continued


No.

Structure


F28




F29




F30




F31



F32



F33




-continued


No.

Structure


F34




F35




F36




F37




F39



F40




-continued



15

15. A molecule according to claim 1 wherein said molecule is selected from one of the molecules in the following Table




-continued


No.

Structure


P5




P6




P7




P8



P9



P10



-continued


No.	Structure
P11	
P12	
P13	
P14	
P15	
P16	

-continued


No.

Structure


P17




P18




P19




P20



P21



P22




-continued


No.

Structure


P23




P24




P25




P26



P27



P28



-continued

No.	Structure
P29	
P30	
P31	

16. A pesticidal composition comprising a molecule according to claim 1 further comprising one or more active ingredients.

17. A pesticidal composition according to claim 16 wherein said active ingredient is from AIGA.

18. A process to control a pest, wherein said process comprising applying to a locus, a pesticidally effective

amount of a pesticidal composition wherein said pesticidal composition comprises a molecule according to claim 1.

19. A process to control endoparasites and/or ectoparasites, wherein said process comprising applying a molecule according to claim 1 to a locus that includes a non-human animal.

* * * * *

Señora Directora

DIRECCION DE NUEVAS CREACIONES

Superintendencia de Industria y Comercio

E. S. D.

Referencia: Expediente No. NC2018/0008756

Solicitud de patente para: MOLÉCULAS QUE TIENEN UTILIDAD

Asunto: PLAGUICIDA, E INTERMEDIARIOS, COMPOSICIONES Y PROCESOS,
RELACIONADOS CON ELLAS

Solicitante: DOW AGROSCIENCES LLC

Fecha de solicitud: 22 de agosto de 2018

MODIFICACIONES VOLUNTARIAS

Yo, **ANDRÉS RINCÓN USCÁTEGUI**, identificado como aparece al pie de mi firma, obrando como apoderado de la sociedad solicitante en el asunto antes identificado, doy alcance a mi memorial de PPH con el fin de modificar el capítulo reivindicatorio actualmente presentado.

De esta forma, se presenta junto con este memorial un nuevo Capítulo Reivindicatorio, que tiene como base tanto el capítulo reivindicatorio actualmente presentado como las enseñanzas de la descripción de la solicitud, tal como se señala a continuación:

1. las antiguas Reivindicaciones 7 a 10 se han eliminado del Capítulo Reivindicatorio;
2. las Reivindicaciones 2 a 12 son nuevas y se encuentran soportadas en las páginas 34, línea 12 a página 35, línea 12 del Capítulo Descriptivo;
3. en la nueva Reivindicación 13, antigua Reivindicación 2 se ha modificado la lista de modalidades preferidas reemplazado el numeral (F) por (G) de modo que todo concuerde con lo presentado en la Descripción;

INNOVACIÓN PARA LOS NEGOCIOS

BOGOTÁ DC, 110221 - COLOMBIA - Edificio Siski - Carrera 4 No. 72A - 35 - Tel. (57-1) 347 3611 - Fax (57-1) 211 8650
MEDELLÍN, 050021 - COLOMBIA - San Fernando Plaza - Carrera 42A No. 1 - 25 Torre 4 Oficina 303 - Teléfono: (57-4) 520 4760
BARRANQUILLA, 080002 - COLOMBIA - Calle 64 No. 50 - 22, Oficina 201 - Teléfono: (57-5) 351 6440
www.cavelier.com
cavelier@cavelier.com

4. en la nueva Reivindicación 16, antigua Reivindicación 5, se modificó la dependencia de modo que ahora depende únicamente de la Reivindicación 1;
5. todas las reivindicaciones, así como sus relaciones de dependencia, fueron reenumeradas de acuerdo con los cambios anteriormente mencionados.

En vista de lo anterior, me permito resaltar que el Capítulo Reivindicatorio modificado se ajusta completamente a lo exigido por el Artículo 34 de la Decisión 486 de 2000, ya que no constituye de ninguna manera una ampliación de la protección que correspondería a la divulgación contenida en la solicitud inicial.

Amablemente solicito a ese Despacho aceptar la modificación aquí presentada y considerar el capítulo reivindicatorio adjunto al presente memorial durante las etapas siguientes del trámite administrativo de la solicitud de patente de referencia.

ANEXOS

1. Pliego reivindicatorio modificado conformado por **17** reivindicaciones;
2. Comprobante de pago por concepto de modificación del pliego reivindicatorio;
3. Pago en línea por concepto de tasa por 7 reivindicaciones adicionales.

Señora Directora,


ANDRÉS RINCÓN USCÁTEGUI

C.C. 79.780.910 de Bogotá

T.P. 114.908

CAPÍTULO REIVINDICATORIO

1. Una molécula que tiene la siguiente fórmula



Fórmula Uno

en donde:

(A) R^1 , R^5 , R^6 , R^{11} , R^{12} , R^{13} , y R^{14} se seleccionan cada uno independientemente del grupo que consiste en H, F, Cl, Br, I, CN, (C₁-C₄) alquilo, (C₁-C₄) haloalquilo, (C₁-C₄) alcoxi, y (C₁-C₄) haloalcoxi;

(B) R^2 , R^3 , y R^4 se seleccionan cada uno independientemente del grupo que consiste en H, F, Cl, Br, I, CN, (C₁-C₄) alquilo, (C₂-C₄) alquenilo, (C₂-C₄) alquinilo, (C₁-C₄) haloalquilo, (C₁-C₄) alcoxi, y (C₁-C₄) haloalcoxi;

(C) R^7 es (C₁-C₆) haloalquilo;

(D) R^9 se selecciona del grupo que consiste en H, F, Cl, Br, I, CN, (C₁-C₄) alquilo, (C₁-C₄) haloalquilo, (C₁-C₄) alcoxi, y (C₁-C₄) haloalcoxi;

(E) R^{10} se selecciona del grupo que consiste en (F), F, Cl, Br, I, CN, (C₁-C₄) alquilo, (C₂-C₄) alquenilo, (C₂-C₄) alquinilo, (C₁-C₄) haloalquilo, (C₁-C₄) alcoxi, y (C₁-C₄) haloalcoxi;

(F) R^9 y R^{10} pueden, opcionalmente, formar juntos un enlace hidrocarbilo de 3 a 5 miembros saturados o no saturados,

en donde dicho enlace hidrocarbilo puede sustituirse opcionalmente con uno o más sustituyentes seleccionados independientemente del grupo que consiste en F, Cl, Br, I, y CN;

(G) L es (C₁-C₆) alquilo;

(H) X se selecciona del grupo que consiste en C, S, y P(C₁-C₆) alquilo;

(I) n es 1 o 2;

(J) R^{15} se selecciona del grupo que consiste en (C₁-C₄) alquilo, (C₂-C₄) alquenilo, (C₃-C₄) cicloalquilo, (C₁-C₄) haloalquilo, (C₁-C₄) alcoxi, (C₁-C₄) haloalcoxi, fenilo, y NH(C₃-C₄) cicloalquilo,

en donde cada alquilo, alquenilo, cicloalquilo, haloalquilo, alcoxi, haloalcoxi, y fenilo puede sustituirse opcionalmente con uno o más sustituyentes seleccionados independientemente del grupo que consiste en F, Cl, Br, I, CN y OH; y

sales de adición de ácido aceptables en la agricultura, derivados de sales, solvatos, derivados de ésteres, polimorfos cristalinos, isótopos, estereoisómeros resueltos y tautómeros, de las moléculas de la Fórmula Uno.







2. Una molécula de acuerdo con la Reivindicación 1, en donde R^1 , R^3 , R^4 , R^5 , R^6 , R^9 , R^{11} , R^{12} , R^{13} y R^{14} son H.
3. Una molécula de acuerdo con la Reivindicación 1, en donde R^2 es Cl, Br o CH_3 .
4. Una molécula de acuerdo con la Reivindicación 1, en donde R^3 es F, Cl, Br o $CH=CH_2$.
5. Una molécula de acuerdo con la Reivindicación 1, en donde R^4 es Cl, Br o CH_3 .
6. Una molécula de acuerdo con la Reivindicación 1, en donde R^2 , R^3 y R^4 son Cl.
7. Una molécula de acuerdo con la Reivindicación 1, en donde R^7 es CF_3 , CF_2CH_3 o $CF_2CH_2CH_3$.
8. Una molécula de acuerdo con la Reivindicación 1, en donde R^{10} es Cl, Br, I, CH_3 o CF_3 .
9. Una molécula de acuerdo con la Reivindicación 1, en donde L es $CH(CH_3)$, o $CH(CH_2CH_3)$.
10. Una molécula de acuerdo con la Reivindicación 1, en donde X es C o S.
11. Una molécula de acuerdo con la Reivindicación 1, en donde n es 1.
12. Una molécula de acuerdo con la Reivindicación 1, en donde R^{15} es CH_2CH_3 , ciclopropil, CH_2CF_3 , $CH_2CH_2CF_3$ o NH ciclopropil.
13. Una molécula de acuerdo con la Reivindicación 1, en donde:
- (A) R^1 , R^5 , R^6 , R^{11} , R^{12} , R^{13} , y R^{14} son H;
 - (B) R^2 , R^3 , y R^4 se seleccionan cada uno independientemente del grupo que consiste en H, F, Cl, Br, (C_1-C_4) alquilo, (C_2-C_4) alquenilo;
 - (C) R^7 es (C_1-C_6) haloalquilo;
 - (D) R^9 es H;
 - (E) R^{10} se selecciona del grupo que consiste en Cl, Br, (C_1-C_4) alquilo, y (C_1-C_4) haloalquilo;
 - (G) L es (C_1-C_6) alquilo;
 - (H) X es C o S;
 - (I) n es 1 o 2;
 - (J) R^{15} se selecciona del grupo que consiste en (C_1-C_4) alquilo, (C_3-C_4) cicloalquilo, (C_1-C_4) haloalquilo, y $NH(C_3-C_4)$ cicloalquilo,

en donde cada alquilo, alquenilo, cicloalquilo, haloalquilo, alcoxi, haloalcoxi, y fenilo puede sustituirse opcionalmente con uno o más sustituyentes seleccionados independientemente del grupo que consiste en F, Cl, Br, I, CN, y OH.







14. Una molécula de acuerdo con la Reivindicación 1 en donde dicha molécula se selecciona de una de la siguiente tabla

No.	Estructura
F1	<chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C/C=C/c2ccc(F)c(c2)C(=O)N[C@H](C)NC(=O)CC(F)(F)F</chem>
F2	<chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C/C=C/c2ccc(C)c(c2)C(=O)N[C@H](C)NC(=O)CC(F)(F)F</chem>
F3	<chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C/C=C/c2ccc(Br)c(c2)C(=O)N[C@H](C)NC(=O)CC(F)(F)F</chem>
F4	<chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C/C=C/c2ccc(Br)cc2C(=O)N[C@H](C)NC(=O)CC(F)(F)F</chem>







F5	<chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C=CC(F)=Cc2ccc(cc2C(F)(F)F)C(=O)N[C@H](C)NC(=O)CC(F)(F)F</chem>
F6	<chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C=CC(F)=Cc2ccc(cc2C)C(=O)N[C@H](C)NC(=O)CC(F)(F)F</chem>
F7	<chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C=CC(F)=Cc2ccc(cc2Cl)C(=O)N[C@H](C)NC(=O)CC(F)(F)F</chem>
F8	<chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C=CC(F)=Cc2ccc(cc2C(F)(F)F)C(=O)N[C@H](C)NC(=O)CC(F)(F)F</chem>
F9	<chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C=CC(F)=Cc2ccc(cc2Cl)C(=O)N[C@H](C)NC(=O)CC(F)(F)F</chem>
F10	<chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C=CC(F)=Cc2ccc(cc2C(F)(F)F)C(=O)N[C@H](C)NC(=O)CC(F)(F)F</chem>

F11	
F12	
F13	
F14	
F15	
F16	

F17	 <chem>Clc1cc(Cl)cc(C(F)(F)C/C=C/c2ccc(cc2)C(F)(F)F)cc1NC[C@H](C)NC(=O)CC(F)(F)F</chem>
F18	 <chem>C=Cc1cc(Cl)cc(C(F)(F)C/C=C/c2ccc(cc2)C(F)(F)F)cc1NC[C@H](C)NC(=O)CC(F)(F)F</chem>
F19	 <chem>Clc1cc(Cl)cc(C(F)(F)C/C=C/c2ccc(cc2)C(F)(F)F)cc1NC[C@H](C)NC(=O)CC(F)(F)F</chem>
F20	 <chem>Clc1cc(Cl)cc(C(F)(F)C/C=C/c2ccc(cc2)C(F)(F)F)cc1NC[C@H](C)NC(=O)CC(F)(F)F</chem>
F21	 <chem>Clc1cc(Cl)cc(C(F)(F)C/C=C/c2ccc(cc2)C(F)(F)F)cc1NC[C@H](C)NC(=O)CC(F)(F)F</chem>
F22	 <chem>Brc1cc(Br)cc(C(F)(F)C/C=C/c2ccc(cc2)C(F)(F)F)cc1NC[C@H](C)NC(=O)CC(F)(F)F</chem>







F23	
F24	
F25	
F26	
F27	
F28	

F29	 <chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C=Cc2ccc3c(c2)C(F)(F)NC[C@H](C)NC(=O)NC4CC4</chem>
F30	 <chem>Brc1cc(Cl)c(Br)cc1C(F)(F)C=Cc2ccc3c(c2)C(F)(F)NC[C@H](C)NC(=O)CC(F)(F)F</chem>
F31	 <chem>Brc1cc(Cl)c(Br)cc1C(F)(F)C=Cc2ccc3c(c2)C(F)(F)NC[C@H](C)NC(=O)CC(F)(F)F</chem>
F32	 <chem>Brc1cc(Br)ccc1C(F)(F)C=Cc2ccc3c(c2)C(F)(F)NC[C@H](C)NC(=O)CC(F)(F)F</chem>
F33	 <chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C=Cc2ccc(C)c3c2C(F)(F)NC[C@H](C)NC(=O)CC(F)(F)F</chem>
F34	 <chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C=Cc2ccc3c(c2)C(F)(F)NC[C@H](C)NC(=O)CC</chem>







F35	
F36	
F37	
F39	
F40	
F41	

15. Una molécula de acuerdo con la Reivindicación 1 en donde dicha molécula se selecciona de una de las moléculas en la siguiente tabla



No.	Estructura
P1	<chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)F/C=C/Fc1ccccc1C(=O)N[C@H](C)NC(=O)CC(F)(F)F</chem>
P2	<chem>Clc1cc(C(F)(F)F)ccc1C(F)(F)F/C=C/Fc1ccc(C(F)(F)F)c(C(=O)N[C@H](C)NC(=O)CC(F)(F)F)c1</chem>
P3	<chem>Clc1cc(C(F)(F)F)ccc1C(F)(F)F/C=C/Fc1ccc(C(F)(F)F)c(C(=O)N[C@H](C)NC(=O)CCCC(F)(F)F)c1</chem>
P4	<chem>Clc1cc(Cl)c(C)cc1C(F)(F)F/C=C/Fc1ccc(C(F)(F)F)c(C(=O)N[C@H](C)NC(=O)CC(F)(F)F)c1</chem>
P5	<chem>Clc1cc(Cl)c(C)cc1C(F)(F)F/C=C/Fc1ccc(C(F)(F)F)c(C(=O)N[C@H](C)NC(=O)CCCC(F)(F)F)c1</chem>

P6	 Chemical structure of compound P6: A 2,6-difluoro-4-(3-(4-chlorophenyl)-2-(trifluoromethyl)prop-1-en-1-yl)benzamide derivative. The structure features a central benzene ring substituted with two fluorine atoms at positions 2 and 6, and a side chain at position 4. The side chain consists of a prop-1-en-1-yl group, where the terminal carbon is substituted with a trifluoromethyl group and a 4-chlorophenyl group. The amide group is attached to the benzene ring at position 1, and the nitrogen atom is substituted with a 1-methyl-2-(2,2,2-trifluoroethyl)carbamoyl group.
P7	 Chemical structure of compound P7: A 2,6-difluoro-4-(3-(4-chlorophenyl)-2-(trifluoromethyl)prop-1-en-1-yl)benzamide derivative. The structure features a central benzene ring substituted with two fluorine atoms at positions 2 and 6, and a side chain at position 4. The side chain consists of a prop-1-en-1-yl group, where the terminal carbon is substituted with a trifluoromethyl group and a 4-chlorophenyl group. The amide group is attached to the benzene ring at position 1, and the nitrogen atom is substituted with a 1-methyl-2-(2,2,2-trifluoroethyl)carbamoyl group.
P8	 Chemical structure of compound P8: A 2,6-difluoro-4-(3-(3-bromo-4-chlorophenyl)-2-(trifluoromethyl)prop-1-en-1-yl)benzamide derivative. The structure features a central benzene ring substituted with two fluorine atoms at positions 2 and 6, and a side chain at position 4. The side chain consists of a prop-1-en-1-yl group, where the terminal carbon is substituted with a trifluoromethyl group and a 3-bromo-4-chlorophenyl group. The amide group is attached to the benzene ring at position 1, and the nitrogen atom is substituted with a 1-methyl-2-(2,2,2-trifluoroethyl)carbamoyl group.
P9	 Chemical structure of compound P9: A 2,6-difluoro-4-(3-(3-bromo-4-chlorophenyl)-2-(trifluoromethyl)prop-1-en-1-yl)benzamide derivative. The structure features a central benzene ring substituted with two fluorine atoms at positions 2 and 6, and a side chain at position 4. The side chain consists of a prop-1-en-1-yl group, where the terminal carbon is substituted with a trifluoromethyl group and a 3-bromo-4-chlorophenyl group. The amide group is attached to the benzene ring at position 1, and the nitrogen atom is substituted with a 1-methyl-2-(2,2,2-trifluoroethyl)carbamoyl group.
P10	 Chemical structure of compound P10: A 2,6-difluoro-4-(3-(3-bromo-4-chlorophenyl)-2-(trifluoromethyl)prop-1-en-1-yl)benzamide derivative. The structure features a central benzene ring substituted with two fluorine atoms at positions 2 and 6, and a side chain at position 4. The side chain consists of a prop-1-en-1-yl group, where the terminal carbon is substituted with a trifluoromethyl group and a 3-bromo-4-chlorophenyl group. The amide group is attached to the benzene ring at position 1, and the nitrogen atom is substituted with a 1-methyl-2-(2,2,2-trifluoroethyl)carbamoyl group.
P11	 Chemical structure of compound P11: A 2,6-difluoro-4-(3-(3-bromo-4-chlorophenyl)-2-(trifluoromethyl)prop-1-en-1-yl)benzamide derivative. The structure features a central benzene ring substituted with two fluorine atoms at positions 2 and 6, and a side chain at position 4. The side chain consists of a prop-1-en-1-yl group, where the terminal carbon is substituted with a trifluoromethyl group and a 3-bromo-4-chlorophenyl group. The amide group is attached to the benzene ring at position 1, and the nitrogen atom is substituted with a 1-methyl-2-(2,2,2-trifluoroethyl)carbamoyl group.

P12	<chem>BrC1=CC=C(C=C1C(F)(F)F)C(F)(F)F/C=C/Fc2ccc(cc2C(F)(F)F)C(F)(F)FNC[C@H](C)NC(=O)CC(F)(F)F</chem>
P13	<chem>BrC1=CC=C(C=C1C(F)(F)F)C(F)(F)F/C=C/Fc2ccc(cc2C(F)(F)F)C(F)(F)FNC[C@H](C)NC(=O)CC(F)(F)F</chem>
P14	<chem>BrC1=CC=C(C=C1C(F)(F)F)C(F)(F)F/C=C/Fc2ccc(cc2C(F)(F)F)C(F)(F)FNC[C@H](C)NC(=O)CC(F)(F)F</chem>
P15	<chem>BrC1=CC=C(C=C1C(F)(F)F)C(F)(F)F/C=C/Fc2ccc(cc2C(F)(F)F)C(F)(F)FNC[C@H](C)NC(=O)CC(F)(F)F</chem>
P16	<chem>BrC1=CC=C(C=C1C(F)(F)F)C(F)(F)F/C=C/Fc2ccc(cc2C(F)(F)F)C(F)(F)FNC[C@H](C)NC(=O)CC(F)(F)F</chem>
P17	<chem>BrC1=CC=C(C=C1C(F)(F)F)C(F)(F)F/C=C/Fc2ccc(cc2C(F)(F)F)C(F)(F)FNC[C@H](C)NC(=O)CC(F)(F)F</chem>

P18	 <chem>Clc1ccc(cc1C(F)(F)F)C(F)(F)C=CC2=CC=C(C(=O)N[C@H](C)NC(=O)CC(F)(F)F)C(F)(F)C2=O</chem>
P19	 <chem>Clc1ccc(cc1C(F)(F)F)C(F)(F)C=CC2=CC=C(C(=O)N[C@H](C)NC(=O)CCC(F)(F)F)C(F)(F)C2=O</chem>
P20	 <chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C=CC2=CC=C(C(=O)N[C@H](C)NC(=O)CC(F)(F)F)C(F)(F)C2=O</chem>
P21	 <chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C=CC2=CC=C(C(=O)N[C@H](C)NC(=O)CCC(F)(F)F)C(F)(F)C2=O</chem>
P22	 <chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C=CC2=CC=C(C(=O)N[C@H](C)NC(=O)CC(F)(F)F)C(F)(F)C2=O</chem>
P23	 <chem>Clc1cc(Cl)c(Cl)cc1C(F)(F)C=CC2=CC=C(C(=O)N[C@H](C)NC(=O)CCC(F)(F)F)C(F)(F)C2=O</chem>

P24	
P25	
P26	
P27	
P28	
P29	

P30	
P31	

16. Una composición plaguicida que comprende una molécula de acuerdo con la Reivindicación 1 que comprende además uno o más ingredientes activos.
17. Una composición plaguicida de acuerdo con la Reivindicación 16 en donde dicho ingrediente activo es de **AIGA**.